| Drug Type Universal CAR-T | 
| Synonyms LMY-921 | 
| Target | 
| Action inhibitors, modulators | 
| Mechanism BAFF-R inhibitors(B-cell activating factor receptor inhibitors), BCMA inhibitors(B-cell maturation protein inhibitors), TACI modulators(Tumor necrosis factor receptor superfamily member 13B modulators) | 
| Therapeutic Areas | 
| Active Indication- | 
| Inactive Indication | 
| Originator Organization | 
| Active Organization- | 
| Inactive Organization | 
| License Organization- | 
| Drug Highest PhaseDiscontinuedPreclinical | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| B-Cell Malignant Neoplasm | Preclinical | United States  | 10 Aug 2022 | 





